Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Circulating tumor cells (CTCs) are crucial for metastasis but their immune evasion mechanisms remain unclear.
• Understanding how CTCs escape immune surveillance is vital for developing effective cancer therapies.

Purpose of the Study:

• To investigate the molecular mechanisms by which pancreatic ductal adenocarcinoma CTCs evade natural killer (NK) cell-mediated immune surveillance.
• To identify therapeutic targets for preventing CTC-driven metastasis.

Main Methods:

• Single-cell transcriptome analysis of pancreatic ductal adenocarcinoma CTCs, primary tumors, and metastatic lesions.
• In vitro and in vivo functional studies involving cell-interaction analysis, immune checkpoint blockade, and gene knockdown.
• Mechanistic investigations into the role of platelet-derived RGS18 and associated signaling pathways (AKT-GSK3β-CREB).

Main Results:

• CTCs interact with NK cells via the immune checkpoint molecule pair HLA-E:CD94-NKG2A.
• Blocking NKG2A or downregulating HLA-E enhances NK cell-mediated tumor cell killing in vitro and prevents metastasis in vivo.
• Platelet-derived RGS18 upregulates HLA-E expression via AKT-GSK3β-CREB signaling, promoting hepatic metastasis.

Conclusions:

• Platelet-derived RGS18 facilitates pancreatic CTC immune evasion by engaging the HLA-E:CD94-NKG2A checkpoint.
• Interrupting this signaling pathway leads to immune elimination of CTCs and prevents tumor metastasis.